Systematic review of health economic evaluation studies on new herpes zoster vaccine among elderly

Surachai Kotirum; Chaniporn Tolertmongkol; Kanyarat Deepaen; Naphatsawan Jongpanyalert; Sikkawat Nakrong

Authors

Surachai Kotirum Social and administrative pharmacy department, College of Pharmacy, Rangsit University, Pathum Thani 12000, Thailand
Chaniporn Tolertmongkol Social and administrative pharmacy department, College of Pharmacy, Rangsit University, Pathum Thani 12000, Thailand
Kanyarat Deepaen Social and administrative pharmacy department, College of Pharmacy, Rangsit University, Pathum Thani 12000, Thailand
Naphatsawan Jongpanyalert Social and administrative pharmacy department, College of Pharmacy, Rangsit University, Pathum Thani 12000, Thailand
Sikkawat Nakrong Social and administrative pharmacy department, College of Pharmacy, Rangsit University, Pathum Thani 12000, Thailand

Keywords:

cost-effectiveness, economic evaluation, herpes zoster vaccine, herpes zoster, systematic review

Abstract

A newer vaccine is generally more expensive than its previous version. Therefore, cost-effectiveness evidence is necessary for considering the implementation of such vaccines into a national health system. This research aimed to collect and analyze economic evaluations of the new herpes zoster vaccine for the elderly published worldwide, regarding the economic value of this vaccine and its context, as supporting evidence for healthcare stakeholders. The authors systematically searched 4 electronic databases, namely Medline, Scopus, Google Scholar, and Google search engine from inception until August 2020. The inclusion criteria is a full economic evaluation, assessing the efficiency of the new herpes zoster vaccine. A standardized form was designed to extract relevant information from all included studies. The authors screened 771 records obtained from the search, and 620 records have been excluded by their titles and abstracts indicating they were not a full economic evaluation study. Then, 151 records were recruited for second-round screening, and 9 full-text studies were finally included. All were conducted in developed countries and used a cost-utility analysis approach. Six studies had shown that the new vaccine against shingles was cost-effective, but 3 studies from the United States, Hong Kong, and Japan indicated cost-ineffective. Under the context of developed countries, the new herpes zoster vaccine offers a good value for money. However, developing countries such as Thailand and Vietnam may need to lower their vaccine prices to be a cost-effective intervention. Health professionals can use these findings for supporting their decision on this vaccine implementation.

References

Arlant, L. H. F., Garcia, M. C. P., Avila Aguero, M. L., Cashat, M., Parellada, C. I., & Wolfson, L. J. (2019). Burden of varicella in Latin America and the Caribbean: Findings from a systematic literature review. BMC Public Health, 19(1), 1–18. https://doi.org/10.1186/s12889-019-6795-0

Aunhachoke, K., Bussaratid, V., Chirachanakul, P., Chua-Intra, B., Dhitavat, J., Jaisathaporn, K., … & Thaipisuttikul, Y. (2011). Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. International Journal of Dermatology, 50(4), 428–435. https://doi.org/10.1111/j.1365-4632.2010.04715.x

Bharucha, T., Houlihan, C. F., & Breuer, J. (2019). Herpesvirus Infections of the Central Nervous System. Seminars in Neurology, 39(3), 369–382. https://doi.org/10.1055/s-0039-1687837

Chiyaka, E. T., Lu, V. T. N., Abhishek, Z., Patricia, D., Mullen, D., & Le, P. (2019). Cost ‑ Effectiveness of Herpes Zoster Vaccination : A Systematic Review. PharmacoEconomics (Vol. 37). Springer International Publishing. https://doi.org/10.1007/s40273-018-0735-1

Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S.-J., Díez-Domingo, J., … & Heineman, T. C. (2016). Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. The New England Journal of Medicine, 375(11), 1019–1032. https://doi.org/10.1056/NEJMoa1603800

Curran, D, Patterson, B., Varghese, L., Van Oorschot, D., Buck, P., Carrico, J., … & Yawn, B. (2018). Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine, 36(33), 5037–5045. https://doi.org/10.1016/j.vaccine.2018.07.005

Curran, D., Patterson, B. J., Van Oorschot, D., Buck, P. O., Carrico, J., Hicks, K. A., ... & Yawn, B. P. (2019). Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live. Human Vaccines and Immunotherapeutics, 15(4), 765–771. https://doi.org/10.1080/21645515.2018.1558689

Damm, O., Ultsch, B., Horn, J., Mikolajczyk, R. T., Greiner, W., & Wichmann, O. (2015). Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health, 15, 533. https://doi.org/10.1186/s12889-015-1861-8

de Boer, P. T., van Lier, A., de Melker, H., van Wijck, A. J. M., Wilschut, J. C., van Hoek, A. J., & Postma, M. J. (2018). Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Medicine, 16(1), 228. https://doi.org/10.1186/s12916-018-1213-5

Drolet, M., Zhou, Z., Sauvageau, C., DeWals, P., Gilca, V., Amini, R., ... & Brisson, M. (2019). Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study. Canadian Medical Association Journal, 191(34), E932-E939. https://doi.org/10.1503/cmaj.190274

Fattore, G., Maniadakis, N., Mantovani, L. G., & Boriani, G. (2011). Health technology assessment: what is it? Current status and perspectives in the field of electrophysiology. Europace, 13(suppl_2), ii49-ii53. https://doi.org/10.1093/europace/eur083

Grahn, A., Studahl, M., Nilsson, S., Thomsson, E., Bäckström, M., & Bergström, T. (2011). Varicella-zoster virus (VZV) glycoprotein E is a serological antigen for detection of intrathecal antibodies to VZV in central nervous system infections, without cross-reaction to herpes simplex virus 1. Clinical and Vaccine Immunology : CVI, 18(8), 1336–1342. https://doi.org/10.1128/CVI.05061-11

Hoshi, S. L., Seposo, X., Shono, A., Okubo, I., & Kondo, M. (2019). Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan. Vaccine, 37(27), 3588-3597. https://doi.org/10.1016/j.vaccine.2019.05.006

Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., … & Loder, E. (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(2), e1-5. https://doi.org/10.1016/j.jval.2013.02.010

Internal Revenue Service. (n.d.). Yearly Average Currency Exchange Rates. Retrieved September 25, 2020, from https://www.irs.gov/individuals/international-taxpayers/yearly-average-currency-exchange-rates

Jeon, Y. H. (2015). Herpes Zoster and Postherpetic Neuralgia: Practical Consideration for Prevention and Treatment. The Korean Journal of Pain, 28(3), 177–184. https://doi.org/10.3344/kjp.2015.28.3.177

Kawai, K., Gebremeskel, B. G., & Acosta, C. J. (2014). Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open, 4(6), e004833. https://doi.org/10.1136/bmjopen-2014-004833

Kawai, K., Yawn, B. P., Wollan, P., & Harpaz, R. (2016). Increasing Incidence of Herpes Zoster Over a 60-year Period From a Population-based Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 63(2), 221–226. https://doi.org/10.1093/cid/ciw296

Lal, H., Cunningham, A. L., Godeaux, O., Chlibek, R., Diez-Domingo, J., Hwang, S.-J., … Heineman, T. C. (2015). Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. The New England Journal of Medicine, 372(22), 2087–2096. https://doi.org/10.1056/NEJMoa1501184

Le, P., & Rothberg, M. B. (2018). Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults. JAMA Internal Medicine, 178(2), 248–258. https://doi.org/10.1001/jamainternmed.2017.7431

McGirr, A., Widenmaier, R., Curran, D., Espié, E., Mrkvan, T., Oostvogels, L., … & Newson, R. S. (2019). The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. Vaccine, 37(22), 2896–2909. https://doi.org/10.1016/j.vaccine.2019.04.014

Prosser, L. A., Harpaz, R., Rose, A. M., Gebremariam, A., Guo, A., Ortega-Sanchez, I. R., … & Dooling, K. (2019). A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Annals of Internal Medicine, 170(6), 380–388. https://doi.org/10.7326/M18-2347

Schmader, K. (2018). Herpes Zoster. Annals of Internal Medicine, 169(3), ITC19–ITC31. https://doi.org/10.7326/AITC201808070

Schmader, K. E., & Dworkin, R. H. (2011). Herpes zoster and postherpetic neuralgia. Essentials of Pain Medicine, 358–364. https://doi.org/10.1016/B978-1-4377-2242-0.00060-2

Schmader, K. E., Levin, M. J., Gnann, J. W. J., McNeil, S. A., Vesikari, T., Betts, R. F., … & Parrino, J. (2012). Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, 54(7), 922–928. https://doi.org/10.1093/cid/cir970

Szucs, T. D., & Pfeil, A. M. (2013). A systematic review of the cost effectiveness of herpes zoster vaccination. PharmacoEconomics, 31(2), 125–136. https://doi.org/10.1007/s40273-012-0020-7

Tavares-Da-Silva, F., Co, M. M., Dessart, C., Hervé, C., López-Fauqued, M., Mahaux, O., … & Stegmann, J. U. (2020). Review of the initial post-marketing safety surveillance for the recombinant zoster vaccine. Vaccine, 38(18), 3489–3500. https://doi.org/10.1016/j.vaccine.2019.11.058

Tricco, A. C., Zarin, W., Cardoso, R., Veroniki, A. A., Khan, P. A., Nincic, V., … & Straus, S. E. (2018). Efficacy, effectiveness, and safety of herpes zoster vaccines in adults aged 50 and older: Systematic review and network meta-analysis. BMJ (Online), 363. https://doi.org/10.1136/bmj.k4029

US Inflation. (n.d.). Consumer Price Index Data from 1913 to 2020. Retrieved September 25, 2020, from https://www.usinflationcalculator.com/inflation/consumer-price-index-and-annual-percent-changes-from-1913-to-2008/

Van Oorschot, D., Anastassopoulou, A., Poulsen Nautrup, B., Varghese, L., von Krempelhuber, A., Neine, M., … & Curran, D. (2019). Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Human Vaccines and Immunotherapeutics, 15(1), 34–44. https://doi.org/10.1080/21645515.2018.1509645

You, J. H., Ming, W. K., Lee, C. F., Tsang, O. T. Y., & Chan, P. K. S. (2018). Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. Vaccine, 36(31), 4610-4620. https://doi.org/10.1016/j.vaccine.2018.06.049